
Management of children in hospital with Acute COVID-19



Birmingham Women's and Children's NHS Foundation Trust

MEDICATIONS

Medication	Dosage	Contraindications & cautions
Dexamethasone	Dose: 150 micrograms/kg once daily maximum 6 mg Route: PO or IV Duration: 10 days or discharge whichever is earlier.	
Hydrocortisone	Dose: 0.5 mg/kg every 12 hours for 7 days and then 0.5mg/kg once daily for 3 days Route: IV Duration: 10 days or until discharge if sooner.	
Sotrovimab	Dose: 500 milligrams Route: IV Duration: Single dose (Note: Dose in RECOVERY trial is 1000 milligrams)	 Known hypersensitivity reaction to the active substances or excipients No dose adjustment required for renal or hepatic impairment
Remdesivir	Dose: Weight 3.5 - 40 kg: 5 mg/kg/ once daily on day 1, followed by 2.5 mg/kg/once daily Weight over 40 kg: 200 mg on day 1, followed by 100 mg once daily Route: IV Duration: 5 days (3 days in Hospital-acquired COVID-19)	 Estimated glomerular filtration rate (eGFR) below 30 ml/minute Alanine aminotransferase (ALT) above 5 times the upper limit of normal at baseline Monitor liver and renal function daily, as dose adjustment/cessation might be required.
Baricitinib	Dose: Age 2 to <9 years: 2mg once daily Age ≥ 9 years: 4 mg daily Route: Oral Duration: 10 days or until discharge if sooner	 Known hypersensitivity to Baricitininb eGFR <15 mL/min/1.73m² ([If the patient is below 9 years of age, this exclusion criteria should be eGFR <30 mL/min/1.73m²] Receiving dialysis or haemofiltration Absolute neutrophil count less than 0.5 x 10⁹ cells/L Active tuberculosis Pregnancy or breastfeeding (undertake pregnancy testing in females of childbearing potential prior to administration) Dose adjustments required in renal impairment and co-administration with certain medications (seek advice from Pharmacy)
Tocilizumab	Dose: Weight below 30 kg: 12 mg/kg single dose Weight above 30 kg 8 mg/kg (max 800 mg) single dose Route: IV Duration: Single dose	 Known hypersensitivity to tocilizumab Liver enzymes [alanine aminotransferase (ALT) or aspartate aminotransferase (AST)] more than ten times the upper limit of normal (caution if more than 1.5 times upper limit of normal) Absolute neutrophil count of less than 1 x 10⁹ /L Platelet count of less than 50 x 10³ /µL Co-existing infection that might be worsened by tocilizumab A pre-existing condition or treatment resulting in ongoing immunosuppression Note: Clinical (fever) and biochemical (CRP) responses to infection might be attenuated post -Tocilizumab. Inform GP and family at discharge of the need to avoid pregnancy and live vaccines for at least 3 months post-Tocilizumab.
Sarilumab	Dose: 400mg Route: IV Duration: Single dose	 Should not have received another IL-6 inhibitor Known hypersensitivity to sarilumab Liver enzymes (ALT or AST) more than 5 times upper limit of normal Platelet count of less than 150 x 10⁹ /L All the above cautions and contraindications as for Tocilizumab
RECOVERY trial medications	Refer to RECOVERY trial protocol https://www.recoverytrial.net/	Note: Sotrovimab dose in RECOVERY trial is 1000 milligrams

Birmingham Women's and Children's NHS Foundation Trust

High risk groups: Conditions listed below indicate increased risk for progression to severe COVID-19; however, these criteria are neither prescriptive nor restrictive.

Please discuss queries and severely ill patients with Paediatric Infectious Diseases service (Drs Hackett/Welch via UHB switchboard).

RCPCH guidance	 Primary immunodeficiency associated with impaired type I interferon signalling 	Other conditions
CYP at significant risk	X-linked agammaglobulinaemia (and other	 High BMI (>95th Centile) Severe respiratory disease (e.g. CF or bronchiectasis with FEV1 <60%) Tracheostomy or long term ventilation Severe asthma (PICU admission in 12 months) Neurodisability and/or neurodevelopmental
Neuro-disability	primary agammaglobulinaemias)	
Complex life-limiting neuro-disability with	Secondary immunodeficiency	
recurrent respiratory infections/ compromise	• HIV CD4 count <200 cells/mm3	
CYP at significant risk if 2 or more of these risk	Solid organ transplant	
factors are present	• HSCT within 12 months, or with GVHD	
Primary immunodeficiency	• CAR-T therapy in last 24 months	
Common variable immunodeficiency (CVID)	 Induction chemotherapy for acute 	disorders
Primary antibody deficiency on	lymphoblastic leukaemia (ALL), non-	Severe cardiac disease
immunoglobulin (or eligible for	Hodgkin's lymphoma, chemotherapy for	Severe chronic kidney disease
immunoglobulin replacement)	acute myeloid leukaemia (AML), relapsed and	Severe liver disease
Hyper-IgM syndromes	/or refractory leukaemia or lymphoma	Sickle Cell disease or other severe
• Good's syndrome (thymoma plus B-cell	Immunosuppressive treatment	haemoglobinopathy
deficiency)	• Chemotherapy within the last 3 months	Trisomy 21
Severe Combined Immunodeficiency (SCID)	• Cyclophosphamide within the last 3 months	Complex genetic or metabolic conditions
Autoimmune polyglandular syndromes	• Corticosteroids >2mg/kg/day for 28 days in	associated with significant comorbidity
/autoimmune polyendocrinopathy,	last 4 weeks	
candidiasis, ectodermal dystrophy (APECED	• B cell depleting treatment in the last 12	 Multiple congenital anomalies associated
syndrome)	months	with significant comorbidity

NHSE guidance

Cohort	Description
Down's syndrome	All patients with Down's syndrome
Sickle cell disease	All patients with a diagnosis of sickle cell disease
Patients with a solid cancer	Active metastatic cancer and active solid cancers (at any stage) All patients receiving chemotherapy within the last 3 months Patients receiving group B or C chemotherapy 3-12 months prior Patients receiving radiotherapy within the last 6 months
Patients with a haematologic malignancy	 Allogeneic haematopoietic stem cell transplant (HSCT) recipients in the last 12 months or active graft vs host disease (GVHD) regardless of time from transplant (including HSCT for non-malignant diseases) Autologous HSCT recipients in the last 12 months (including HSCT for non-malignant diseases) Individuals with haematological malignancies who have o received chimaeric antigen receptor (CAR)-T cell therapy in the last 12 months. Individuals with haematological malignancies receiving systemic anti-cancer treatment (SACT) within the last 12 months except patients with chronic phase chronic myeloid leukaemia (CML) in molecular response or first or second line tyrosine kinase inhibitors (TKI). All patients with myeloma (excluding MGUS) or chronic B-cell lymphopoliferative disorders (e.g. chronic lymphocytic leukaemia, follicular lymphoma) or myelodysplastic syndrome (MDS) who do not fit the criteria above. All patients with sickle cell disease. Individuals with nor-malignant haematological disorder (e.g. anti-CD20, anti-chymocyte globulin [ATG] and alemtumab) within the last 12 months.
Patients with renal disease	 Renal transplant recipients (including those with failed transplants within the past 12 months), particularly those who: Received B cell depleting therapy within the past 12 months (including alemtuzumab, rituximab [anti-CD20], anti-thymocyte globulin) Have an additional substantial risk factor which would in isolation make them eligible for nMABs or oral antivirals Not been vaccinated prior to transplantation Non-transplant patients with of the set or 5 (an eGR less than 30 ml/min/1.73m2) without immunosuppression
Patients with liver disease	 Patients with cirrhosis Child's-Pugh class B and C (decompensated liver disease). Patients with a liver transplant Liver patients on immune suppressive therapy (including patients with and without liver cirrhosis) Patients with cirrhosis Child's-Pugh class A who are not on immune suppressive therapy (compensated liver disease)
Patients with immune- mediated inflammatory disorders (IMID)	 IMID treated with rituximab or other 8 cell depleting therapy in the last 12 months IMID with active/unstable disease on corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate. IMID with stable disease on either corticosteroids, cyclophosphamide, tacrolimus, cyclosporin or mycophenolate. IMID patients with active/unstable disease including those on biological monotherapy and on combination biologicals with thiopurine or methotrexate
Primary immune deficiencies	Common variable immunodeficiency (CVID) Undefined primary antibody deficiency on immunoglobulin (or eligible for Ig) Hyper-IgM syndromes Good's syndrome (thymoma plus B-cell deficiency) Severe Combined Immunodeficiency (SCID) Autoimmune polyglandular syndromes/autoimmune polyendocrinopathy, candidiasis, ectodermal dystrophy (APECED syndrome) Primary immunodeficiency associated with impaired type I interferon signalling X-linked agammaglobulinaemia (and other primary agammaglobulinaemias)
HIV/AIDS	 Patients with high levels of immune suppression, have uncontrolled/untreated HIV (high viral load) or present acutely with an AIOS defining diagnosis On treatment for HIV with CD4 <350 cells/mm3 and stable on HIV treatment or CD4>350 cells/mm3 and additional risi factors (e.g. age, diabetes, obesity, cardiovascular, liver or renal disease, homeless, those with alcohol-dependence)
Solid organ transplant recipients	All recipients of solid organ transplants not otherwise specified above
Rare neurological conditions	Multiple sclerosis Motor neurone disease Myasthenia gravis Huntington's disease

References: (contains detailed information for guiding clinical care)

- 1. NICE COVID-19 guidance: https://www.nice.org.uk/guidance/ng191/resources/covid19-rapid-guideline-managing-covid19-pdf-51035553326
- 2. RCPCH COVID-19 guidance: <u>https://www.rcpch.ac.uk/resources/covid-19-guidance-acute-settings</u>

3. MHRA-CAS Clinical pathway: Therapies for patients hospitalised due to COVID-19 <u>https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103203</u>

- 4. Interim Clinical Commissioning Policy: **Baricitinib** for patients hospitalised due to COVID-19 (adults and children aged 2 years and over) 5 May 2022 https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103203
- 5. Interim Clinical Commissioning Policy: **Neutralising monoclonal antibodies and intravenous antivirals** in the treatment of COVID-19 in hospitalised patients https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103196
- NHSE clinical commissioning policy for Remdesivir https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103197
- NHSE clinical commissioning policy for Tocilizumab https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103194
- NHSE clinical commissioning policy for Sarilumab:
 Hyperson and the second sec
- https://www.cas.mhra.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=103194
- 9. RECOVERY trial: <u>https://www.recoverytrial.net/</u>
 10. Local Anticoagulation policy

Dr Deepthi Jyothish (<u>deepthi.jyothish@nhs.net</u>) Rhian Isaac (<u>rhian.isaac@nhs.net</u>)

17/05/2022